Long‐term biological effects in sickle cell disease: insights from a post‐crizanlizumab study
Darla Liles(University of North Carolina at Chapel Hill), Abdullah Kutlar(Augusta University), Brandon M. Hardesty(Indiana Hemophilia and Thrombosis Center), Shelley E. Crary(Arkansas Children's Hospital), Sharada A. Sarnaik(Wayne State University), Wally R. Smith(Virginia Commonwealth University), Payal Desai(Levine Cancer Institute), Walter K. Kraft(Thomas Jefferson University), Vince D. Cataldo(Louisiana State University), Geetha Puthenveetil(City Of Hope National Medical Center), Brigid Scullin(University of North Carolina Health Care), Alan K. Ikeda(Baxalta (United States)), Julie Kanter(University of Alabama at Birmingham), Natasha M. Archer(Boston Children's Hospital), Nirmish Shah(Duke University), Modupe Idowu(The University of Texas Health Science Center at Houston), Ralph V. Boccia(Center for Cancer and Blood Disorders), Kathryn L. Hassell(University of Colorado Denver), Maureen M. Achebe(Brigham and Women's Hospital), Victor R. Gordeuk(University of Illinois Chicago)
Cited by 5
Related Papers
Management of Sickle Cell Disease
|JAMA|2014|1.6k
Sickle cell disease
|Nature Reviews Disease Primers|2018|1.4k
Hemochromatosis and Iron-Overload Screening in a Racially Diverse Population
|New England Journal of Medicine|2005|774
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761